Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for Nail Psoriasis
NCT04535999Phase 4Completed
- Sponsor
- University of Pennsylvania
- Start
- Feb 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in psoriasis, sponsored by University of Pennsylvania. Started Feb 2022; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04535999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535999.